Skip to content

US · RIGL · BIOTECHNOLOGY

Rigel Pharmaceuticals, Inc. (RIGL) intrinsic value and stock valuation

$40.09as of 2026-11-21 · Mkt cap 748.96M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rigel Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values RIGL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RIGL’s statements →

Rigel Pharmaceuticals, Inc. Graham Number

Graham Number: $99.96d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 rigel.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$294.3M+22.1% 5y CAGRd
20112025
Net income
$367M
20112025
Free cash flow
$75.7M
20112025
Total equity
$391.5M+63% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$294.3M$179.3M$116.9M$120.2M$149.2M
Operating income$125.5M$24.2M-$-20.49M-$-55.55M-$-12.5M
Net income$367M$17.5M-$-25.09M-$-58.57M-$-17.91M
EPSd$19.5M$988.1K-$-1.44M-$-3.4M-$-1.05M
Operating cash flow$75.7M$31.5M-$-5.74M-$-73.76M$5.88M
Capital expenditure$0.00-$-400K-$-15M-$-450K-$-630K
Free cash flow$75.7M$31.1M-$-20.74M-$-74.21M$5.25M
Total assets$513.6M$164M$117.2M$134.3M$167.3M
Total debt$53.3M$60M$60.6M$41.6M$30.6M
Net debt$12.7M$3.22M$27.8M$17.1M$11.7M
Total equity$391.5M$3.29M-$-28.64M-$-13.62M$30.4M
Cash and short-term investments$155M$77.3M$56.9M$58.2M$125M
Income statement
20252024202320222021
Revenue$294.3M$179.3M$116.9M$120.2M$149.2M
Cost of revenue$19.6M$18.7M$7.11M$1.75M$1.08M
Gross profit$274.7M$160.6M$109.8M$118.5M$148.2M
Research and development expenses$33.3M$23.4M$24.5M$60.3M$65.2M
Selling, general and administrative expenses$115.9M$113.1M$105.7M$112.5M$91.9M
Other expenses$0.00$0.00$0.00$1.32M$3.52M
Operating expenses$149.2M$136.4M$130.3M$174M$160.7M
Cost and expenses$168.8M$155.1M$137.4M$175.8M$161.7M
Interest income$3.68M$2.09M$2.27M$680K$50K
Interest expense$7.32M$7.92M$6.87M$3.71M$4.86M
Depreciation and amortization$2.42M$2.23M$1.24M$1M$1.16M
Ebitda$131.6M$28.5M-$-16.98M-$-53.87M-$-11.29M
Operating income$125.5M$24.2M-$-20.49M-$-55.55M-$-12.5M
Total other income/expenses, net-$-3.64M-$-5.83M-$-4.6M-$-3.02M-$-4.81M
Income before tax$121.8M$18.4M-$-25.09M-$-58.57M-$-17.31M
Income tax expense-$-245.2M$880K$0.00$0.00$600K
Net income$367M$17.5M-$-25.09M-$-58.57M-$-17.91M
Weighted average shares outstanding$18M$17.6M$17.4M$17.2M$17.1M
Weighted average diluted shares outstanding$18.8M$17.7M$17.4M$17.2M$17.1M
Balance sheet
20252024202320222021
Cash and short-term investments$155M$77.3M$56.9M$58.2M$125M
Net receivables$51.8M$41.6M$30.6M$40.3M$15.5M
Inventory$11.5M$6M$5.52M$9.12M$6.62M
Total current assets$240.2M$135.1M$99.3M$115.9M$154.5M
Property, plant and equipment, net$920K$340K$1.03M$2.79M$11.9M
Goodwill and intangible assets$24.8M$27.1M$13.9M$15M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$273.4M$28.9M$18M$18.4M$12.9M
Total assets$513.6M$164M$117.2M$134.3M$167.3M
Accounts payable$7.19M$3.34M$7.14M$22.5M$3.79M
Short-term debt$30.4M$7.56M$7.92M$1.13M$9.89M
Deferred revenue$1.35M$27.8M$17M$13.5M$10.5M
Total current liabilities$99.2M$63.3M$53.3M$65.2M$63.6M
Long-term debt$22.9M$52.4M$52.7M$40.4M$20.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.9M$97.4M$92.6M$82.7M$73.4M
Capital lease obligations$400K$280K$980K$2.1M$10.7M
Total liabilities$122.1M$160.7M$145.9M$147.9M$137M
Common stock$20K$20K$20K$170K$170K
Retained earnings-$-1.02B-$-1.39B-$-1.41B-$-1.38B-$-1.32B
Accumulated other comprehensive income (loss)$180K$10K$10K-$-150K-$-100K
Total equity$391.5M$3.29M-$-28.64M-$-13.62M$30.4M
Total investments$114.4M$20.6M$24.2M$33.8M$106.1M
Total debt$53.3M$60M$60.6M$41.6M$30.6M
Net debt$12.7M$3.22M$27.8M$17.1M$11.7M
Cash flow statement
20252024202320222021
Net income$367M$17.5M-$-25.09M-$-58.57M-$-17.91M
Depreciation and amortization$2.42M$2.23M$1.24M$1M$1.16M
Stock-based compensation$12.7M$12.4M$8.81M$12.4M$9.49M
Change in working capital-$-19.51M$150K$9.52M-$-29.05M$9.72M
Accounts receivable-$-10.15M-$-11.06M$9.77M-$-24.85M$500K
Inventory-$-5.63M$760K$1.17M-$-2.38M-$-4.88M
Accounts payable$3.85M-$-3.8M-$-370K$3.79M$40K
Net cash provided by operating activities$75.7M$31.5M-$-5.74M-$-73.76M$5.88M
Investments in property, plant and equipment$0.00-$-400K-$-15M-$-450K-$-630K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-92.36M$4.13M-$-4.3M$72.8M-$-80.04M
Common stock issued$8.1M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-10M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$600K-$-11.64M$18.4M$6.55M$62.7M
Net change in cash-$-16.11M$24M$8.33M$5.57M-$-11.48M
Cash at end of period$40.6M$56.8M$32.8M$24.5M$18.9M
Operating cash flow$75.7M$31.5M-$-5.74M-$-73.76M$5.88M
Capital expenditure$0.00-$-400K-$-15M-$-450K-$-630K
Free cash flow$75.7M$31.1M-$-20.74M-$-74.21M$5.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rigel Pharmaceuticals, Inc.

        Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

        CEO
        Raul R. Rodriguez
        Employees
        174
        Beta
        1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Rigel Pharmaceuticals, Inc. (RIGL)?

        Rigel Pharmaceuticals, Inc. (RIGL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RIGL undervalued?

        RIGL trades at a price of $40.09 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.